Published research on Metformin hydrochloride

5 peer-reviewed publications on Metformin hydrochloride in oncology research, clinical work first, then laboratory studies. Each entry reports what the authors stated; follow the link for the full paper.

1. Clinical trial

   Effect of Metformin vs Placebo on Invasive Disease-Free Survival in Patients With Breast Cancer: The MA.32 Randomized Clinical Trial

   Goodwin PJ et al., JAMA, 2022

   In 3649 patients with high-risk nonmetastatic breast cancer without diabetes, five years of adjuvant metformin did not improve invasive disease-free survival compared with placebo in hormone receptor-positive disease (hazard ratio 1.01, 95% CI 0.84 to 1.21, P = .93), and futility was declared for hormone receptor-negative disease.

2. Clinical trial

   Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial

   Skinner H et al., JAMA Oncology, 2021

   In 167 non-diabetic patients with unresectable stage III non-small cell lung cancer, adding metformin to chemoradiation was well tolerated but did not improve 1-year progression-free survival (51.3% vs 60.4%, hazard ratio 1.15, P = .24) or overall survival.

3. Clinical trial

   Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial

   Higurashi T et al., Lancet Oncology, 2016

   In 151 non-diabetic patients randomized after polypectomy, one year of low-dose metformin was associated with a lower prevalence of total polyps (38.0% vs 56.5%, risk ratio 0.67) and adenomas (30.6% vs 51.6%) at follow-up colonoscopy compared with placebo.

4. Observational

   Metformin and reduced risk of cancer in diabetic patients

   Evans JM et al., BMJ, 2005

   In a pilot case-control study of patients with type 2 diabetes in Tayside, Scotland, any exposure to metformin was associated with a lower odds of cancer (unadjusted odds ratio 0.79, 95% CI 0.67 to 0.93).

5. Meta-analysis

   Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders

   Gandini S et al., Cancer Prevention Research, 2014

   Across 47 independent studies with 65,540 cancer cases in patients with diabetes, metformin use was associated with a 31% reduction in cancer incidence and a 34% reduction in cancer mortality, with smaller reductions in BMI-adjusted studies and studies without time-related biases and no consistent reductions for individual organ sites.

Metformin hydrochloride in the catalog (specifications, pack sizes, Certificate of Analysis)